Results 121 to 130 of about 81,723 (303)

Successful treatment of eosinophilic esophagitis with upadacitinib prescribed for atopic dermatitis

JPGN Reports, EarlyView.
Abstract We describe a pediatric patient treated with upadacitinib for atopic dermatitis (AD) who subsequently achieved sustained clinical and histologic remission of eosinophilic esophagitis (EoE). Upadacitinib is an oral small molecule selective Janus kinase 1 inhibitor that inhibits janus kinase‐signal transduction and activation of transcription ...
Nathalie Nguyen, Maureen Bauer
wiley   +1 more source

The safe and effective use of tofacitinib and ustekinumab combination therapy in infantile onset inflammatory bowel disease

JPGN Reports, EarlyView.
Abstract Infantile‐onset inflammatory bowel disease (IOIBD) is a rare and severe subset of very‐early‐onset IBD, often associated with immune dysregulation and poor response to conventional therapies. Data regarding the use of Janus kinase inhibitors (JAKI) in this population is limited.
Smridhi Mahajan, Christian Wysocki, Bhaskar Gurram   +2 more
wiley   +1 more source

Profile of pacritinib and its potential in the treatment of hematologic disorders

Journal of Blood Medicine, 2014
Eleftheria Hatzimichael, Evangelos Tsolas, Evangelos Briasoulis Department of Haematology, University Hospital of Ioannina, Ioannina, Greece Abstract: Pacritinib (previously known as SB-1518) is an innovative selective inhibitor of Janus kinase 2 and ...
Hatzimichael E, Tsolas E, Briasoulis E
doaj  

Systemic Absorption and Pharmacokinetics of Five Novel Topical Dermatologic Agents: A Review

JEADV Clinical Practice, EarlyView.
ABSTRACT In recent years, innovative topical medications with novel mechanisms of action have emerged to treat common dermatologic conditions such as acne, atopic dermatitis, vitiligo, and actinic keratoses. These molecularly targeted therapies offer improved safety and tolerability compared to traditional options like corticosteroids.
Mary Dyson, Kara Hurley, Hannah Chaudhury, Lara Shehadeh, Cameron West   +4 more
wiley   +1 more source

New Biologic and Small Molecule Therapies for Hidradenitis Suppurativa

JEADV Clinical Practice, EarlyView.
ABSTRACT Hidradenitis suppurativa (HS) is an inflammatory skin disease that has historically been underdiagnosed and, until recently, under‐researched. Furthermore, the pathophysiology of HS is complex, and not fully understood. Just three biologic medications—adalimumab (anti‐TNF‐α), secukinumab (anti‐IL17A) and bimekizumab (anti‐IL17A/F) are licensed
Emily Pender, Rosalind Hughes, Brian Kirby   +2 more
wiley   +1 more source

Efficacy of Lebrikizumab in Patients With Severe Atopic Dermatitis Who Would be Eligible for Treatment Based on the South Korean Reimbursement Criteria

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Lebrikizumab is approved to treat patients with moderate‐to‐severe atopic dermatitis (AD). Objectives This study evaluated the 16‐week efficacy outcomes of lebrikizumab in adults and adolescents with severe AD in ADvocate trials who would be eligible for treatment based on South Korean reimbursement‐like criteria. Methods This was a
Chong Hyun Won, Chun Wook Park, Jiyoung Ahn, Joo Yeon Ko, Sang Hyun Cho, Yang Won Lee, Joo Hee Lee, Khai Jing Ng, Min Young Hong, Jinglin Zhong, Martin Dossenbach, Sang Wook Son   +11 more
wiley   +1 more source

JAK Inhibitors in Psoriatic–Atopic Dermatitis Overlap: A Four‑Case Series

JEADV Clinical Practice, EarlyView.
ABSTRACT Overlap between psoriasis and atopic dermatitis (AD) poses diagnostic and therapeutic challenges; monoclonal antibodies targeting a single axis may improve one component while worsening the other [1]. Janus kinase (JAK) inhibitors act pleiotropically and may provide simultaneous control of psoriatic and eczematous inflammation [2].
Eleonora Bongiovanni, Francois Rosset, Isotta Giunipero di Corteranzo, Lorenzo Bellando, Rebecca Senetta, Simone Ribero, Pietro Quaglino   +6 more
wiley   +1 more source

REVEAL AD ‐ Prevalence of Moderate and Severe Atopic Dermatitis in Ireland: A Cross‐ Sectional, Real World Study of a Secondary Care Population

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Atopic dermatitis (AD) is a common inflammatory skin disease. However, limited data exist on its prevalence and incidence in Irish secondary care. Objectives REVEAL AD had two distinct but related objectives: (1) Estimate prevalence of moderate‐to‐severe AD in patients aged 12 years and older presenting to secondary care clinics in ...
Oisín S. Gough, Fiona McEvoy, Moneeb Saddiq, Michael O'Connell, Maeve Lynch, Brian Kirby, Michelle Murphy   +6 more
wiley   +1 more source

LncRNA NORAD Enhances Inflammatory Injury in Sepsis‐Associated Acute Lung Damage Through miR‐150‐5p/STAT1‐Dependent NF‐κB Activation

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Acute lung injury (ALI) is a severe complication of sepsis, yet the role of lncRNA NORAD in its pathogenesis remains unclear. Using LPS‐stimulated BEAS‐2B and HBEC3‐KT cells as well as cecal ligation and puncture (CLP)‐induced ALI models in C57BL/6 mice, we found that NORAD expression was markedly upregulated and promoted cell injury ...
Han Liu, Xi‐Xi Chen, Gui‐Hua Wei, Feng Li, Hai‐Yan Zong   +4 more
wiley   +1 more source

Vaccarin Improves Myocardial Ischemia–Reperfusion Injury by Attenuating Oxidative Stress and Ferroptosis Through Reducing NOX4‐Modulated JAK2/STAT3 Pathway Activation

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Vaccarin is a naturally occurring flavonoid glycoside with cardioprotective properties; however, its involvement in myocardial ischemia–reperfusion (MI/R) injury remains poorly defined. We herein investigated whether vaccarin protects cardiomyocytes from MI/R‐induced dysfunction in vivo and in vitro and examined the associated molecular ...
Han Yang, Mi Zhou, Feng‐Cai Zhang
wiley   +1 more source